The study team examined lenabasum (JBT-101), a selective cannabinoid receptor type 2 (CB2) agonist, in a well-established polymicrobial sepsis model. They induced sepsis using cecal ligation and puncture (CLP) and focused on the acute 24-hour phase after induction. Thirty male Wistar rats were allocated to five groups: Sham, CLP, CLP + lenabasum 1 mg/kg, CLP + lenabasum 5 mg/kg, and CLP + dexamethasone 1 mg/kg. Interventions were administered intraperitoneally after sepsis induction. The authors reported that assessments at 24 hours included lung oxidative/antioxidant indices, serum markers of inflammation and resolution, and blinded histopathological scoring. The paper did not provide data beyond the acute 24-h window, and it did not report experiments testing receptor blockade to prove CB2 dependence.
Lung reactive oxygen species (ROS), malondialdehyde (MDA), and reduced glutathione (GSH) were the selected redox endpoints. CLP increased lung ROS and MDA and decreased GSH relative to Sham, consistent with oxidative stress in sepsis-associated acute lung injury. Both doses of lenabasum lowered MDA compared with untreated CLP. The 5 mg/kg dose produced additional effects: the study team observed a reduction in lung ROS and an increase in GSH at 24 hours. The lower 1 mg/kg dose did not report the same pattern for ROS and GSH. Dexamethasone was included as a comparator; the abstract describes lenabasum effects alongside dexamethasone but does not present comparative statistical values in the abstract text. The source did not report receptor-blocking studies to determine whether these redox changes required CB2 activation.
Serum tumor necrosis factor-alpha (TNF-α), interleukin-8 (IL-8), and C-reactive protein (CRP) were measured as pro-inflammatory markers. The inflammation–resolution panel also included lipoxin A4 (LXA4), a specialized pro-resolving mediator. CLP elevated TNF-α, IL-8, CRP and LXA4 at 24 hours compared with Sham, indicating a systemic inflammatory response together with activation of some resolution pathways. Both lenabasum doses reduced serum inflammatory markers and shifted LXA4 levels toward Sham values. The authors reported these changes in the abstract; the paper indicates directionality and group effects but the abstract does not present exact numeric values or p-values for each comparison. The study therefore documents modulation of the serum inflammation–resolution profile by lenabasum at the 24-h acute phase.
Lung tissue was processed for hematoxylin-eosin staining and evaluated under blinded conditions using a lung injury score (LIS). CLP produced histopathological lung injury by 24 hours. Both lenabasum doses reduced LIS relative to untreated CLP, according to the authors. The 5 mg/kg dose produced a more pronounced attenuation of histopathological damage; the team observed that 5 mg/kg lenabasum attenuated histopathological lung injury in addition to improving redox indices. The authors used dexamethasone 1 mg/kg as a pharmacologic comparator; the abstract notes its inclusion but does not provide detailed head-to-head outcome data in the summary text. All histology assessments reported in the abstract were performed blinded to group assignment.
This report covers the acute 24-hour phase only. The investigators did not report longer-term outcomes, survival data, or functional respiratory measures in the abstract. The authors specifically noted that the receptor dependence of lenabasum’s effects remains to be established; the source did not describe receptor-blocking or genetic knockout experiments to confirm CB2 mediation. Dose-ranging beyond the two tested doses and time-course studies were not detailed in the abstract. The paper concludes that lenabasum, particularly at 5 mg/kg, attenuated biochemical disturbances and histopathological lung injury at 24 h after CLP and that further preclinical investigation is warranted — with receptor-dependence, time course, and functional respiratory endpoints identified as outstanding questions.